Report Date: 07 February 2026
Subject: Fundamental Equity Research Report – Gujarat Themis Biosyn Ltd.
Here is the deep fundamental analysis of Gujarat Themis Biosyn Ltd. based on the latest available market data and financial results (Q3 FY26 declared on Feb 05, 2026).
🧬 Stock Analysis: Gujarat Themis Biosyn Ltd.
(NSE: GUJTHEMIS | BSE: 506879)
⚠️ KEY UPDATE (Feb 2026): Company ne haal hi mein (Oct 2025) apni Fermentation Capacity Double ki hai aur forward integration (API manufacturing) start kiya hai. Q3 FY26 ke results mixed aaye hain (Revenue Up, Profit Down).
1️⃣ Business Model & Work
- Core Business: Gujarat Themis Biosyn (GTBL) ek Fermentation-based API company hai. Ye “Complex Chemistry” me deal karti hai jise replicate karna mushkil hai.
- Key Products:
- Rifamycin S: Ye tuberculosis (TB) ki dawai “Rifampicin” banane ke liye ek critical intermediate hai.
- Rifamycin O: Ye “Rifaximin” (Irritable Bowel Syndrome / Diarrhea) banane ke liye use hota hai.
- New Strategy: Pehle ye company sirf “Contract Manufacturing” (Job work) karti thi, lekin ab ye “Manufacture and Sell” model par shift ho gayi hai, jisse margins badhe hain. Ab ye API (Finished Product) bhi banane lage hain.
- Clients: Inka sabse bada client Lupin Ltd hai (Rifampicin global leader). Iske alawa Optrix Labs aur exports markets par focus hai.
- Moat: Fermentation technology master karna mushkil hai aur high capex lagta hai, isliye is field me naye competitors aasani se nahi aate.
2️⃣ Industry & Sector Analysis
- Sector Status: Pharmaceuticals (Niche API / Fermentation).
- Cyclical vs Secular? Secular. TB (Tuberculosis) eradication global priority hai (WHO & Govt of India targets). Isliye demand constant rahti hai.
- Growth Drivers:
- China+1 Strategy: Fermentation products ke liye duniya China par depend thi. Ab India me supply chain shift ho rahi hai.
- Forward Integration: Company ab sirf Raw Material (Intermediate) nahi, balki final API bana kar export market (Europe/USA) target kar rahi hai.
3️⃣ Latest Financial Performance (Standalone)
(Figures in ₹ Crores | Latest: Q3 FY26 Results – Declared Feb 05, 2026)
| Metric | FY 2024 | FY 2025 | Q2 FY26 (Sep ’25) | Q3 FY26 (Dec ’25) | Trend (YoY) |
| Revenue | 174 | 162 | 43.1 | 43.4 | ↗️ Up 9.7% |
| Operating Profit | 88 | 82 | 21.7 | 21.7 | ↔️ Flat |
| OPM % | 50% | 50% | 50.4% | 49.1% | ⚠️ Slight Dip |
| Net Profit (PAT) | 58 | 56 | 14.3 | 12.5 | 📉 Down 4% |
| EPS (₹) | 4.02 | 3.85 | 0.98 | 0.86 | 📉 Dip |
- Analysis (Q3 FY26 – Feb 2026 Data):
- Revenue Growth: Revenue YoY ~10% badha hai, jo dikhata hai ki nayi capacity (Oct 2025) se volume aana shuru ho gaya hai.
- Profit Pressure: Revenue badhne ke bawajood Net Profit 4% gira hai (YoY).
- Reason: Company ne bataya ki “New Labour Codes” aur operational costs badhne se margins par slight pressure aaya hai. Nayi plant start hone par initial depreciation aur cost absorption ka impact bhi hai.
- High Margins: Operating Margin abhi bhi 49% hai, jo pharma industry me exceptional mana jata hai.
4️⃣ Management & Shareholding (Latest Pattern)
- Promoter Holding:70.86% (Strong).
- Promoters: Themis Medicare Ltd aur Pharmaceutical Business Group.
- Pledge Update (Jan 2026): Promoter entity (Themis Medicare) ne recently ~3.5 Lakh shares pledge kiye hain (total encumbered ~1.38%). Ye ek minor negative point hai, lekin alarming nahi hai.
- FII Holding:~1.96% (Decreased slightly).
- Foreign investors ne pichle kuch quarters me stake thoda trim kiya hai.
- DII Holding: 0.01% (Negligible).
- Management Focus: Management ka pura focus “Non-China” supply chain banne par hai. Unhone aggressive Capex (Capacity Expansion) kiya hai internal accruals (bina loan) se.
5️⃣ Valuation (Premium Pricing)
(Current Market Price: ~₹320 – ₹325 | Market Cap: ~₹3,550 Cr)
| Metric | Gujarat Themis Biosyn | Themis Medicare (Parent) | Concord Biotech |
| P/E Ratio | ~70x – 74x | ~35x | ~45x |
| P/B Ratio | ~13x | ~5x | ~8x |
| EV / EBITDA | ~40x | ~18x | ~30x |
| ROCE | ~35% | ~18% | ~22% |
- Interpretation:
- Very Expensive: Stock 74x PE par trade kar raha hai. Market isse “High Growth” stock maan kar premium de raha hai.
- Risk: Itni high valuation par agar growth thodi bhi slow hoti hai (jaisa Q3 me profit gira), to stock price me sharp correction aa sakta hai.
- Justification? Premium valuation isliye hai kyunki inke margins (50%) aur ROCE (35%) industry leading hain.
6️⃣ Future Growth Triggers (3–5 Years)
- Capacity Expansion (Live Now): October 2025 me inki fermentation capacity 450 KL se badhkar 990 KL (doubled) ho gayi hai. Iska full revenue impact FY27 se dikhega.
- API Forward Integration: Ab tak ye sirf intermediate bechte the. Ab ye khud API banayenge, jisse export market open hoga (Europe/USA).
- New Products: Rifamycin series ke alawa company naye fermentation-based products par R&D kar rahi hai taaki single-product dependency kam ho.
7️⃣ Present Situation (Current Outlook)
- Stock Phase: Consolidation / Time Correction. Stock apne high (~₹479) se girkar ₹320 ki range me stabilize ho raha hai.
- Short Term Trend: Q3 earnings me profit drop hone se sentiment thoda weak hai. Market wait karega ki nayi capacity se sales kab accelerate hoti hai.
- Outlook: Business strong hai, lekin price abhi earnings se aage bhaag chuka hai.
8️⃣ Risk & Red Flags (⚠️ Critical)
- Product Concentration: Revenue ka bada hissa sirf Rifamycin family se aata hai. Agar TB treatment protocols change hote hain ya koi naya drug aata hai, to business risk me aa sakta hai.
- Client Concentration: Lupin Ltd par heavy dependency hai.
- Valuation Risk: 74x PE sustainable nahi hai agar earnings growth 20-25% CAGR se nahi aayi. Current growth (Flat/Negative profit) valuation ko justify nahi karti.
- Pledge: Promoter pledge ka introduction (chahe chota ho) monitor karna zaroori hai.
9️⃣ Final Verdict
- Summary: Gujarat Themis Biosyn ek High Quality Franchise hai with superior margins (50%) aur clean balance sheet. Company ne capacity double ki hai jo future growth confirm karti hai. Lekin, current price (PE 70x+) par ye saari growth already priced-in lag rahi hai.
- For Long-Term Investors: HOLD / ACCUMULATE ON DEEP DIPS. Aggressive buying na karein. Ideal entry level valuations cool-off hone par (PE 40-50x range) banega. Current price par risk-reward ratio thoda unfavourable hai.
- For Aggressive Investors: Breakout ka wait karein. Jab tak quarterly profit growth wapas double-digit me nahi aati, stock range-bound reh sakta hai.
- Target Range: ₹400 – ₹450 (18-24 Months) – Conditional on successful utilization of new capacity.
Next Step for You: Would you like me to track the “Rifamycin Prices” trend globally? Kyunki prices girne par inke margins turant impact honge.
Disclaimer: Ye article sirf educational purpose ke liye hai. Kisi bhi nivesh se pehle apne Financial Advisor se salah zarur lein.